{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:14:39Z","timestamp":1778649279976,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurological disorders have overlapping clinical manifestations, creating an urgent need for accessible biomarkers to aid differential diagnosis. Interleukin-6 (IL-6) is a core neuroinflammatory mediator, yet its expression profile across the full spectrum of neurological disorders remains poorly characterized in large-scale cohorts using a uniform detection platform. We aimed to map serum IL-6 levels across 10 categories of neurological disorders, with healthy individuals as controls, identify its independent predictors, and evaluate its multi-scenario diagnostic performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational non-interventional cohort study at Renmin Hospital of Wuhan University (a tertiary academic medical center in Wuhan, China) enrolling 6,465 individuals (515 healthy controls, 5,950 patients across 10 neurological disease categories) who underwent serum IL-6 testing via cytometric bead array (CBA) between January 2018 and September 2025. Statistical analyses included Kruskal\u2013Wallis test, multivariable linear regression, receiver operating characteristic (ROC) curve analysis, and decision curve analysis (DCA). Nested logistic regression models were constructed to evaluate the incremental diagnostic value of IL-6 beyond age and sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum IL-6 levels showed significant heterogeneity across disease categories (p &amp;lt; 0.001). The highest elevations were observed in traumatic brain injury (TBI), metabolic\/toxic encephalopathy, and hemorrhagic stroke (median: 59.93, 28.41, 24.09 pg\/mL), with only mild increases in neurodegenerative diseases and intracranial tumors. Disease category, age (U-shaped association), and male sex were independent predictors of IL-6 levels (all p &amp;lt; 0.001). IL-6 achieved good diagnostic performance for distinguishing TBI (AUC 0.974), metabolic\/toxic encephalopathy (AUC 0.940), and hemorrhagic stroke (AUC 0.925) from healthy status; notably, IL-6 showed limited discriminatory power for differential diagnosis between TBI and other neurological diseases (AUC\u00a0=\u00a00.741). Incorporating age and sex significantly improved discrimination for CNS infections (\u0394AUC = 0.129, p &amp;lt; 0.0001), with the age+sex-only model achieving an AUC of 0.785 (95% CI 0.75\u20130.82).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large-scale cohort study, we demonstrate that serum IL-6 is a neuroinflammatory biomarker with robust efficacy for screening acute brain injury from healthy status. Its clinical interpretation requires age- and sex-stratified reference intervals, and it holds potential as a preliminary screening indicator for acute neurological conditions in specific clinical settings. The diagnostic utility of IL-6 in unselected emergency triage settings, as well as the proposed clinical interpretation framework, require prospective validation in multi-center, real-world cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1825206","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:48:54Z","timestamp":1778647734000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum interleukin-6 as a neuroinflammatory biomarker across the spectrum of neurological disorders: a large-scale retrospective cohort study of 6,465 individuals"],"prefix":"10.3389","volume":"17","author":[{"given":"Lingjun","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoming","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengliang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adx0043","article-title":"Neuroinflammation across neurological diseases","volume":"388","author":"Shi","year":"2025","journal-title":"Sci (New York NY)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70514","article-title":"Cytokines and immune biomarkers in neurodegeneration and cognitive function: A systematic review among individuals of African ancestry","volume":"21","author":"Antwi","year":"2025","journal-title":"Alzheimer's Dementia: J Alzheimer's Assoc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2251490","article-title":"The essential role of neuroimaging in diagnosing and managing cerebrovascular disease in Africa: a review","volume":"55","author":"Aderinto","year":"2023","journal-title":"Ann Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1692719","article-title":"Eye-tracking during free visual exploration of familiar dramatic character faces facilitates rapid and accurate stroke recognition","volume":"19","author":"Lu","year":"2025","journal-title":"Front Neurosci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e318214a81f","article-title":"Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury","volume":"68","author":"Bohmer","year":"2011","journal-title":"Neurosurgery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol Neurodegener"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103826","article-title":"Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab","volume":"24","author":"Li","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12974-024-03129-0","article-title":"Exploratory assessment of the effect of systemic administration of soluble glycoprotein 130 on cognitive performance and chemokine levels in a mouse model of experimental traumatic brain injury","volume":"21","author":"Gober","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e200095","DOI":"10.1212\/nxi.0000000000200095","article-title":"Levels of soluble interleukin 6 receptor and Asp358Ala are associated with cognitive performance and Alzheimer disease biomarkers","volume":"10","author":"Quillen","year":"2023","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2029675","article-title":"Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6\/IL-6Ralpha to inhibit IL-6\/ IL-6Ralpha\/gp130 hexameric signaling complex formation","volume":"14","author":"Chou","year":"2022","journal-title":"mAbs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"eabc3480","DOI":"10.1126\/scisignal.abc3480","article-title":"Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T(H)17 cell expansion","volume":"14","author":"Heise","year":"2021","journal-title":"Sci Signaling"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400533","article-title":"The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions","volume":"15","author":"Kerkis","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12974-024-03246-w","article-title":"Astrocytic DLL4-NOTCH1 signaling pathway promotes neuroinflammation via the IL-6-STAT3 axis","volume":"21","author":"Mora","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1343503","article-title":"Bystander activation of microglia by Brucella abortus-infected astrocytes induces neuronal death via IL-6 trans-signaling","volume":"14","author":"Rodriguez","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.125.051455","article-title":"Blood-brain barrier disruption predicts poor outcome in subarachnoid hemorrhage: A dynamic contrast-enhanced MRI study","volume":"56","author":"Llull","year":"2025","journal-title":"Stroke"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2024.136028","article-title":"Blood-brain barrier damage accelerates the accumulation of micro- and nanoplastics in the human central nervous system","volume":"480","author":"Xie","year":"2024","journal-title":"J Hazard Mater"},{"key":"B18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.bbi.2025.06.021","article-title":"IL-6 trans-signalling is elevated in ALS models and drives TDP-43 induced inflammatory responses in microglia","volume":"129","author":"Risby-Jones","year":"2025","journal-title":"Brain Behavior Immun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2022.08.019","article-title":"Interleukin-6 trans-signalling in hippocampal CA1 neurones mediates perioperative neurocognitive disorders in mice","volume":"129","author":"Hu","year":"2022","journal-title":"Br J Anaesthesia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2023.08.026","article-title":"Selective blockade of interleukin 6 trans-signaling depresses atrial fibrillation","volume":"20","author":"Li","year":"2023","journal-title":"Heart Rhythm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12974-025-03365-y","article-title":"Inhibition of IL-6 trans-signaling promotes post-stroke functional recovery in a sex and dose-dependent manner","volume":"22","author":"Hall","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae230","article-title":"Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias","volume":"148","author":"Cai","year":"2025","journal-title":"Brain: A J Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbi.2023.06.027","article-title":"Associations of neuroinflammatory IL-6 and IL-8 with brain atrophy, memory decline, and core AD biomarkers - in cognitively unimpaired older adults","volume":"113","author":"Capogna","year":"2023","journal-title":"Brain Behavior Immun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12974-022-02467-1","article-title":"Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study","volume":"19","author":"Li","year":"2022","journal-title":"J Neuroinflamm"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2024.0611","article-title":"Advances in circulating biomarkers for neurodegenerative diseases, traumatic brain injuries, and central nervous system tumors","volume":"45","author":"Yang","year":"2025","journal-title":"Ann Lab Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13049-025-01430-2","article-title":"Interleukin-6 and its association with outcome in traumatic brain injury: a prospective cohort","volume":"33","author":"Caceres","year":"2025","journal-title":"Scandinavian J Trauma Resuscitation Emergency Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2023.0135","article-title":"Interleukin-6 in traumatic brain injury: A Janus-faced player in damage and repair","volume":"40","author":"Ciryam","year":"2023","journal-title":"J Neurotrauma"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2024.06.014","article-title":"Plasma IL-6 levels and their association with brain health and dementia risk: A population-based cohort study","volume":"120","author":"Zhao","year":"2024","journal-title":"Brain Behavior Immun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2024.1174","article-title":"Neuroinflammation as a link in Parkinson's and Alzheimer's diseases: A systematic review and meta-analysis","volume":"16","author":"Tylutka","year":"2024","journal-title":"Aging Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/0271678x16630991","article-title":"In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use","volume":"36","author":"Helms","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 revisited: From rheumatoid arthritis to CAR T cell therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41581-023-00787-w","article-title":"Mechanisms and consequences of sex differences in immune responses","volume":"20","author":"Dunn","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-016-3046-3","article-title":"A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury","volume":"159","author":"Thelin","year":"2017","journal-title":"Acta Neurochirurgica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-021-01678-z","article-title":"S100B, GFAP, UCH-L1 and NSE as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy","volume":"45","author":"Amoo","year":"2022","journal-title":"Neurosurgical Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"a028415","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 family cytokines","volume":"10","author":"Rose-John","year":"2018","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/acssensors.4c02257","article-title":"Ultrasensitive electrochemical vertical flow immunoassay for rapid and simultaneous detection of interleukin-6 and procalcitonin","volume":"9","author":"Ying","year":"2024","journal-title":"ACS Sens"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2024.117077","article-title":"All-in-one microfluidic immunosensing device for rapid and end-to-end determination of salivary biomarkers of cardiovascular diseases","volume":"271","author":"Liang","year":"2025","journal-title":"Biosens Bioelectron"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00256-3","article-title":"Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study","volume":"21","author":"Korley","year":"2022","journal-title":"Lancet Neurol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-026-04050-1","article-title":"Correlation between peripheral and central inflammatory and neuronal injury markers in mild cognitive impairment patients: the role of blood-brain barrier status","author":"Liu","year":"2026","journal-title":"Transl Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1123407","article-title":"Inflammatory cytokines associated with mild traumatic brain injury and clinical outcomes: a systematic review and meta-analysis","volume":"14","author":"Malik","year":"2023","journal-title":"Front Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/bios12121095","article-title":"A proof-of-concept electrochemical skin sensor for simultaneous measurement of glial fibrillary acidic protein (GFAP) and interleukin-6 (IL-6) for management of traumatic brain injuries","volume":"12","author":"Shahub","year":"2022","journal-title":"Biosensors"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2021.0011","article-title":"The known unknowns: An overview of the state of blood-based protein biomarkers of mild traumatic brain injury","volume":"38","author":"McDonald","year":"2021","journal-title":"J Neurotrauma"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155832","article-title":"Interleukin-6 classic and trans-signaling utilize glucose metabolism reprogramming to achieve anti- or pro-inflammatory effects","volume":"155","author":"Xu","year":"2024","journal-title":"Metab Clin Exp"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1212\/nxi.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurology(R) Neuroimmunol Neuroinflamm"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2014.34.4.263","article-title":"Update on procalcitonin measurements","volume":"34","author":"Meisner","year":"2014","journal-title":"Ann Lab Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/jalm\/jfad007","article-title":"AACC guidance document on the clinical use of procalcitonin","volume":"8","author":"Chambliss","year":"2023","journal-title":"J Appl Lab Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825206\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:49:03Z","timestamp":1778647743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825206\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1825206"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1825206","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1825206"}}